Want to see JNJ full AI Analyst Report?

Johnson & Johnson (JNJ) Price & Analysis

28,248 Followers

JNJ Stock Chart & Stats

$234.18

-$4.08(-2.79%)

At close: Jan 08 4:00 PM EST

$234.18

-$4.08(-2.79%)

Day’s Range― - ―

52-Week Range$154.80 - $269.43

Previous CloseN/A

Volume3.80M

Average Volume (3M)8.43M

Market Cap

$623.71B

Enterprise Value$597.07B

Total Cash (Recent Filing)$22.05B

Total Debt (Recent Filing)$54.99B

Price to Earnings (P/E)29.6

Beta-0.04

Next Earnings

Jul 15, 2026

EPS Estimate

2.86

Next Dividend Ex-DateN/A

Dividend Yield2.5%

Share Statistics

EPS (TTM)8.67

Shares Outstanding2,407,217,000

10 Day Avg. Volume7,684,211

30 Day Avg. Volume8,425,993

Financial Highlights & Ratios

PEG Ratio0.21

Price to Book (P/B)6.18

Price to Sales (P/S)5.35

P/FCF Ratio25.59

Enterprise Value/Market Cap0.96

Enterprise Value/Revenue6.20

Enterprise Value/Gross Profit8.96

Enterprise Value/Ebitda17.83

Forecast

1Y Price Target

$268.07

Price Target Upside14.47% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering16

EPS Forecast (FY)11.59

Revenue Forecast (FY)$101.04B

Bulls Say, Bears Say

Bulls Say

Durable Revenue GrowthJohnson & Johnson has demonstrated steady top-line expansion over multiple years, reflecting broad-based demand across Pharmaceuticals and MedTech. This multi-year revenue trend indicates a resilient commercial footprint and diversified product mix that supports durable growth absent short-term market moves.

High, Sustainable ProfitabilityConsistently elevated margins across the enterprise point to structural pricing power, efficient scale in manufacturing and R&D, and a portfolio biased to higher-margin pharmaceuticals. These margin levels underpin strong earnings power and long-term capacity to fund innovation and shareholder returns.

Strong Cash Generation & Capital ReturnsLarge absolute free cash flow and a sizable cash balance enable sustained dividend growth, reinvestment and capex plans (including a multi‑year U.S. manufacturing/R&D program). Reliable cash generation supports capital allocation flexibility and long-term strategic investments.

Bears Say

Material STELARA ErosionA very large, rapid decline in a legacy blockbuster due to biosimilars and new-class adoption highlights structural vulnerability: loss of entrenched revenue can meaningfully depress growth and forces reliance on launches to replace material cash flows over multiple years.

Margin Deleverage From Sustained Launch InvestmentManagement is deploying heavier SG&A and launch spend to support new products, which materially compresses margins. If launches take longer to ramp or mix remains unfavorable, sustained investment intensity could keep margins below prior peaks and limit near-term cash conversion.

Weaker Cash-flow Momentum & Timing VolatilityWhile absolute cash generation is large, recent FCF decline and OCF being well below net income signal working-capital swings and timing effects. That reduces predictability of free cash flow, complicating durable planning for buybacks, dividends and capex absent execution improvement.

Johnson & Johnson News

Federal health role nominee has record of vaccine skepticism, Stat News reports

Sean Kaufman, who has been nominated to be Assistant Secretary for Preparedness and Response for the Trump administration,...

21h ago

AZN

EBS

Johnson & Johnson price target raised to $263 from $254 at BofA

BofA raised the firm’s price target on Johnson & Johnson to $263 from $254 and keeps a Neutral...

1d ago

JNJ

3 ‘Strong Buy’ Dividend Aristocrat Stocks, According to Top Analysts — July 9, 2026

Johnson & Johnson ($JNJ), Chevron ($CVX), and Cintas ($CTAS) are three Dividend Aristocrat stocks with a Strong Buy...

2d ago

CVX

JNJ

Best ETFs to Invest In, According to AI Analyst, 7/8/2026

Exchange-traded funds (ETFs) provide an attractive investment option to gain exposure to stocks, bonds, sectors, commodities, and global...

3d ago

JNJ

VYM

Johnson & Johnson announces FDA approval for THERMOCOOL SMARTTOUCH SF

Johnson & Johnson announced that the U.S. Food and Drug Administration approved the Dual Energy THERMOCOOL SMARTTOUCH SF...

3d ago

JNJ

Johnson & Johnson price target raised to $284 from $283 at Morgan Stanley

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Johnson & Johnson to $284 from $283...

3d ago

JNJ

Johnson & Johnson price target raised to $298 from $285 at Citi

Citi raised the firm’s price target on Johnson & Johnson to $298 from $285 and keeps a Buy...

3d ago

JNJ

Jim Cramer Says Five Stocks Are In a ‘Great Place to Do Some Buying’

Jim Cramer listed five stocks worth buying and all of them have rallied following his comments. ...

4d ago

JNJ

PEP

Protagonist Therapeutics price target raised to $145 from $121 at Truist

Truist raised the firm’s price target on Protagonist Therapeutics (PTGX) to $145 from $121 and keeps a Buy...

4d ago

JNJ

PTGX

Johnson & Johnson price target raised to $290 from $280 at HSBC

HSBC raised the firm’s price target on Johnson & Johnson to $290 from $280 and keeps a Buy...

5d ago

JNJ

Best ETFs to Invest In, According to AI Analyst, 7/1/2026

Exchange-traded funds (ETFs) have become one of the most popular investment options, offering diversification, the flexibility to trade...

10d ago

AI Daily: Amazon’s AWS commits $1B toward new unit

Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies...

11d ago

AZN

BMY

Anthropic takes aim at pharma industry with Claude Science, STAT reports

Anthropic has launched Claude Science, a version of its AI tailored for scientific and pharmaceutical research, marking a...

11d ago

AZN

BMY

The Week That Was, The Week Ahead: Macro and Markets, June 28

Stocks ended the week lower as investors pulled back from risk assets and rotated into safer parts of...

13d ago

JNJ FAQ

What was Johnson & Johnson’s price range in the past 12 months?

Johnson & Johnson lowest stock price was $154.80 and its highest was $269.43 in the past 12 months.

What is Johnson & Johnson’s market cap?

Johnson & Johnson’s market cap is $623.71B.

When is Johnson & Johnson’s upcoming earnings report date?

Johnson & Johnson’s upcoming earnings report date is Jul 15, 2026 which is in 4 days.

How were Johnson & Johnson’s earnings last quarter?

Johnson & Johnson released its earnings results on Apr 14, 2026. The company reported $2.7 earnings per share for the quarter, beating the consensus estimate of $2.677 by $0.023.

Is Johnson & Johnson overvalued?

According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Johnson & Johnson pay dividends?

Johnson & Johnson pays a Quarterly dividend of $1.34 which represents an annual dividend yield of 2.5%. See more information on Johnson & Johnson dividends here

What is Johnson & Johnson’s EPS estimate?

Johnson & Johnson’s EPS estimate is 2.86.

How many shares outstanding does Johnson & Johnson have?

Johnson & Johnson has 2,407,217,000 shares outstanding.

What happened to Johnson & Johnson’s price movement after its last earnings report?

Johnson & Johnson reported an EPS of $2.7 in its last earnings report, beating expectations of $2.677. Following the earnings report the stock price went up 0.899%.

Which hedge fund is a major shareholder of Johnson & Johnson?

Currently, no hedge funds are holding shares in JNJ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Johnson & Johnson Stock Smart Score

Outperform

Fundamentals

Return on Equity

26.26%

Trailing 12-Months

Asset Growth

3.73%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson (JNJ) Earnings & Revenues

Historic Earnings Reports

JNJ Company Deck

JNJ Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call presented a broadly positive commercial and pipeline story: strong top-line operational growth, multiple high-growth products (DARZALEX, CARVYKTI, TECVAYLI, TALVEY, RYBREVANT, TREMFYA) and successful new launches (ICOTYDE, INLEXZO) with raised full‑year guidance and clear long‑term targets (line of sight to double‑digit growth by decade end). Offsetting these positives were significant short‑term headwinds—most notably a steep STELARA decline, GAAP EPS volatility driven by prior-year one‑time items, margin deleverage from heavier launch investments and a soft Q1 free cash flow run‑rate. Management emphasized confidence in recovery/acceleration through the year, substantial R&D and manufacturing investments, and multiple upcoming catalysts, leading to an overall constructive outlook despite near‑term profitability and comparability pressures.View all JNJ earnings summaries

JNJ Sales Breakdown

64.12% Innovative Medicine

35.88% MedTech

JNJ Stock 12 Month Forecast

Average Price Target

$268.07

▲(14.47% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"151":"$151","188":"$188","225":"$225","262":"$262","299":"$299"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":298,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$298.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":268.07142857142856,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$268.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":250,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$250.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[151,188,225,262,299],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,253.98,257.36615384615385,260.7523076923077,264.1384615384615,267.5246153846154,270.91076923076923,274.29692307692306,277.6830769230769,281.0692307692308,284.4553846153846,287.84153846153845,291.2276923076923,294.61384615384617,{"y":298,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,253.98,255.06395604395604,256.14791208791206,257.2318681318681,258.31582417582416,259.3997802197802,260.48373626373626,261.5676923076923,262.65164835164836,263.73560439560435,264.8195604395604,265.90351648351646,266.9874725274725,{"y":268.07142857142856,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,253.98,253.67384615384614,253.3676923076923,253.06153846153845,252.7553846153846,252.44923076923075,252.1430769230769,251.83692307692309,251.53076923076924,251.2246153846154,250.91846153846154,250.6123076923077,250.30615384615385,{"y":250,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":152.993,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.189,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.121,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.898,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.685,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.254,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.855,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":229.529,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":248.56,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":244.12,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":227.19,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":223.51,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":253.98,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >